WTA to introduce mandatory SRY gene test for female players

The Women's Tennis Association (WTA) has announced a new eligibility policy requiring players to undergo a one-time test for the SRY gene, which determines biological sex, in order to compete on the women's tour.

The updated policy takes effect on Tuesday, according to a WTA statement. Players who refuse the mandatory screening will face disciplinary action. Testing is scheduled to begin in 2026, following data privacy safeguards and a player engagement programme.

The change replaces previous WTA rules that allowed transgender women to participate provided their declared gender was female and they maintained a lower testosterone level for two years before competing. The WTA noted there are no known transgender women currently on the tour or in professional tennis.

What the new policy involves

• One-time mandatory screening for the SRY gene to confirm biological sex
• Disciplinary action for players who refuse to take the test
• Screening begins in 2026, after confidentiality and privacy safeguards are in place
• Follows similar SRY testing policies adopted by World Athletics and World Boxing in 2025

In its statement, the WTA said the policy is intended to provide a clear eligibility standard for participation in its tournaments. The organisation acknowledged that the issue is sensitive and complex, adding that it is committed to treating all players with dignity and implementing the policy respectfully.

The announcement marks a significant shift in eligibility rules for women's tennis and aligns the sport with other governing bodies that have introduced biological sex testing. The full rollout and player response will be closely watched as the 2026 testing window approaches.